Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine

@article{Kress2009ClinicalUO,
  title={Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine},
  author={Hans G. Kress},
  journal={European Journal of Pain},
  year={2009},
  volume={13}
}
  • Hans G. Kress
  • Published 2009
  • Medicine
  • European Journal of Pain
Buprenorphine was not used widely in clinical practice over many years, mainly due to analgesic potency and clinical safety concerns based on misinterpreted animal data. Contrary to previous concerns, however, no analgesic ceiling effect and no antagonism of combined pure μ‐opioid receptor agonists is seen within the therapeutic dose range. In recent studies, buprenorphine could be effectively and safely combined with full μ‐agonists, and switching between buprenorphine and another opioid… Expand
Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile
  • J. Pergolizzi, A. Aloisi, +10 authors Avi A. Weinbroum
  • Medicine
  • Pain practice : the official journal of World Institute of Pain
  • 2010
TLDR
Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain, and its favorable safety profile and proven efficacy in severe pain and favorable tolerability mean that it can be considered a safe and effective option for treating chronic cancer and noncancer pain. Expand
Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
TLDR
Mounting evidence from clinical studies and conclusions drawn by a panel of experts strongly support superior safety and efficacy profile of buprenorphine vs marketed opioids. Expand
Buprenorphine 5, 10 and 20 μg/h Transdermal Patch
TLDR
Transdermal buprenorphine has generally demonstrated good efficacy and tolerability in clinical trials in chronic non-malignant pain, providing effective background analgesia as part of pain management strategies for patients with osteoarthritis, low back pain and other persistent pain syndromes of at least moderate severity. Expand
A Review of its Use in the Management of Chronic Non-Malignant Pain
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2492
Transdermal buprenorphine – a critical appraisal of its role in pain management
TLDR
Mounting evidence indicates the appropriateness of Bup TDS in the treatment of diverse acute and chronic pain syndromes which have been less or not responsive to other opioids. Expand
Safety and Efficacy of Buprenorphine Patch in the Management of Chronic Pain
A transdermal formulation of buprenorphine was introduced in 2001, which reignited interest in this medication for the treatment of chronic moderate-to-severe pain. This review presents the evidenceExpand
Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain
TLDR
This work has compared the analgesic and anti‐hyperalgesic effects of buprenorphine and fentanyl. Expand
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
TLDR
Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids. Expand
Clinical Use of Buprenorphine for Anesthesia and Pain Management in Japan
TLDR
Buprenorphine is useful for postoperative pain relief in patients with severe liver dysfunction in Japan, however, the prolonged metabolism of BUP and occurrence of delayed emergence from anesthesia may occur in these patients. Expand
Buprenorphine—Clinically useful but often misunderstood
  • S. Butler
  • Medicine
  • Scandinavian journal of pain
  • 2013
TLDR
Buprenorphine’s unusual pharmacodynamics and pharmacokinetics make it an ideal opioid for treatment of most chronic pain conditions where opioid therapy is indicated, and it will continue to be an attractive alternative to methadone for opioid abuse rehabilitation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 140 REFERENCES
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.
TLDR
Studies characterizing buprenorphine's pharmacodynamic actions, including its safety, abuse liability, withdrawal suppression and withdrawal precipitation capacity, physical dependence potential, cross-tolerance and duration of action as well as a review of the pharmacological profile of bupenorphine/naloxone combinations are reviewed. Expand
Transdermal buprenorphine in the management of persistent pain – safety aspects
  • R. Likar
  • Medicine
  • Therapeutics and clinical risk management
  • 2006
TLDR
Transdermal buprenorphine (Gruenenthal GmbH, Aachen, Germany) provides a noninvasive method of rate-controlled drug release ensuring constant and predictable serum bupenorphine levels over a prolonged period, which has been shown to be advantageous for long-term treatment of chronic pain patients providing reliable pain control, few adverse events, and good patient acceptance. Expand
Buprenorphine: considerations for pain management.
TLDR
Buprenorphine, a partial mu-opioid agonist which has been in clinical use for over 25 years, has been found to be amenable to new formulation technology based on its physiochemical and pharmacological profile. Expand
Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients
TLDR
In six patients, dose increments of TD-BUP were effective, and patients achieved adequate analgesia within 6 days, and it cannot be excluded that even higher doses may be effective, as some patients required rapid titration with higher morphine equivalent doses. Expand
Buprenorphine in cancer pain
TLDR
The recent development of a polymer matrix patch delivery system for buprenorphine prevents “dose dumping” and facilitates pain management in those unable to take oral analgesics. Expand
Transdermal buprenorphine in pain management – experiences from clinical practice: five case studies
  • F. Louis
  • Medicine
  • International journal of clinical practice
  • 2006
TLDR
Four cases of chronic, non‐malignant pain, and one case of chronic cancer pain were presented and transdermal buprenorphine matrix patches provided effective analgesia and were well tolerated. Expand
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
TLDR
Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics. Expand
Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
TLDR
Buprenorphine TDS was shown to be an effective analgesic against chronic, severe pain in this study population and showed improved duration of sleep and reduced need for additional oral analgesics. Expand
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
TLDR
Intensive intravenous morphine (IV-MO) was effective and safe in most cancer patients receiving TTS-BUP who experienced pain exacerbation and intensity was not relevant. Expand
Transdermal buprenorphine. Commentaries
TLDR
Despite the availability of rescue medication to all patients, those receiving transdermal buprenorphine tended to experience greater pain relief, reduced pain intensity and longer pain-free sleep, and the requirement for rescue medication was reduced from baseline in >50% of patients treated with transderMAL bupenorphine, in two trials. Expand
...
1
2
3
4
5
...